Literature DB >> 19471257

Idiopathic portal hypertension in patients with HIV infection treated with highly active antiretroviral therapy.

Pik-Eu Chang1, Rosa Miquel, Jose-Luis Blanco, Montserrat Laguno, Miguel Bruguera, Juan-G Abraldes, Jaime Bosch, Juan-Carlos Garcia-Pagan.   

Abstract

OBJECTIVES: Idiopathic portal hypertension (IPH) is the presence of PH in the absence of liver disease. Recently, IPH was reported in HIV patients on highly active antiretroviral therapy (HAART). We describe for the first time the hepatic and systemic hemodynamic profile, liver stiffness, and histological features of eight patients with HIV-related IPH.
METHODS: HIV-positive patients were identified from our IPH database over 3 years.
RESULTS: Five patients presented with variceal bleeding, two with splenomegaly, and one with ascites. All had large esophageal varices. Median hepatic venous pressure gradient (HVPG) was 8 mm Hg (range 3.5-14.5), clearly underestimating the true portal pressure. This is probably because of a presinusoidal component of PH and because of the presence of intrahepatic venous collaterals. Median liver stiffness was 8.9 kPa (range 6.8-14.9) and was unreliable in predicting the presence of fibrosis or of esophageal varices. The main histological features were absence of portal vein radicles and areas of regenerating hepatocytes. Six patients (75%) developed portal vein thrombosis during a 2-year follow-up.
CONCLUSIONS: There is a subset of HIV patients without cirrhosis but with PH compatible with IPH. In these patients, the hepatic and systemic hemodynamic profile is similar to other forms of IPH. The histological profile reflects an underlying vascular disorder affecting the medium-sized portal vein branches. Development of portal vein thrombosis is a frequent complication and requires close monitoring.

Entities:  

Mesh:

Year:  2009        PMID: 19471257     DOI: 10.1038/ajg.2009.165

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  22 in total

1.  Didanosine Exposure and Noncirrhotic Portal Hypertension in a HIV Clinic in North America: a Follow-up Study.

Authors:  Edward R Cachay; Michael R Peterson; Miguel Goicoechea; William C Mathews
Journal:  Br J Med Med Res       Date:  2011

2.  Spectrum of histopathological changes in patients with non-cirrhotic portal fibrosis.

Authors:  Abhijit Chougule; Archana Rastogi; Rakhi Maiwall; Chhagan Bihari; Vikrant Sood; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2018-04-12       Impact factor: 6.047

3.  Risk factors for liver fibrosis among human immunodeficiency virus monoinfected patients using the FIB4 index in Morocco.

Authors:  Mohamed Tahiri; Mustapha Sodqi; Fatima Ez Zahra Lahdami; Latifa Marih; Hassan Lamdini; Wafaa Hliwa; Ahd Oulad Lahcen; Wafaa Badre; Fouad Haddad; Abdelfetah Chakib; Ahmed Bellabah; Rhimou Alaoui; Kamal Marhoum El Filali
Journal:  World J Hepatol       Date:  2013-10-27

4.  The development of hepatoportal sclerosis and portal hypertension due to didanosine use in HIV.

Authors:  Thomas D Schiano; Alison Uriel; Douglas T Dieterich; M Isabel Fiel
Journal:  Virchows Arch       Date:  2010-11-06       Impact factor: 4.064

Review 5.  Idiopathic Non-Cirrhotic Intrahepatic Portal Hypertension (NCIPH)-Newer Insights into Pathogenesis and Emerging Newer Treatment Options.

Authors:  Ashish Goel; Joshua E Elias; Chundamannil E Eapen; Banumathi Ramakrishna; Elwyn Elias
Journal:  J Clin Exp Hepatol       Date:  2014-07-28

Review 6.  Idiopathic portal hypertension and extrahepatic portal venous obstruction.

Authors:  Rajeev Khanna; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2018-02-20       Impact factor: 6.047

Review 7.  Clinical applications, limitations and future role of transient elastography in the management of liver disease.

Authors:  Pik Eu Chang; George Boon-Bee Goh; Jing Hieng Ngu; Hiang Keat Tan; Chee Kiat Tan
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

8.  Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.

Authors:  Helen Kovari; Caroline A Sabin; Bruno Ledergerber; Lene Ryom; Signe W Worm; Colette Smith; Andrew Phillips; Peter Reiss; Eric Fontas; Kathy Petoumenos; Stéphane De Wit; Philippe Morlat; Jens D Lundgren; Rainer Weber
Journal:  Clin Infect Dis       Date:  2012-10-22       Impact factor: 9.079

Review 9.  Human immunodeficiency virus and nodular regenerative hyperplasia of liver: A systematic review.

Authors:  Archita Sood; Mariana Castrejón; Sammy Saab
Journal:  World J Hepatol       Date:  2014-01-27

10.  Anticoagulant therapy for nodular regenerative hyperplasia in a HIV-infected patient.

Authors:  Florian Bihl; Filip Janssens; Francoise Boehlen; Laura Rubbia-Brandt; Antoine Hadengue; Laurent Spahr
Journal:  BMC Gastroenterol       Date:  2010-01-18       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.